Quest Diagnostics' Recent Developments and Financial Performance

Quest Diagnostics’ Recent Developments and Financial Performance

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, has recently reported significant financial growth and strategic advancements. As of July 6, 2026, the company’s stock price stands at $213.45, reflecting a slight decrease of 1.02% from the previous close.

First Quarter 2026 Financial Results

In the first quarter of 2026, Quest Diagnostics reported revenues of $2.90 billion, marking a 9.2% increase from the same period in 2025. This growth was predominantly organic, with a 9.0% rise in organic revenue. The reported diluted earnings per share (EPS) for the quarter was $2.24, up 15.5% from the previous year, while the adjusted diluted EPS stood at $2.50, reflecting a 13.1% increase. These robust results led the company to raise its full-year 2026 guidance, now expecting reported diluted EPS between $9.58 and $9.78, and adjusted diluted EPS between $10.63 and $10.83.

Strategic Collaborations and Acquisitions

Quest Diagnostics has been actively pursuing strategic collaborations to enhance its service offerings. In September 2025, the company announced a collaboration with Epic, a leading electronic health record (EHR) system provider. This partnership aims to streamline laboratory testing experiences for healthcare providers and patients by integrating Quest’s services with Epic’s EHR platform. The collaboration is expected to improve service efficiency and patient engagement through features like simplified appointment scheduling and enhanced transparency in health plan reimbursements.

Additionally, in August 2025, Quest completed the acquisition of select clinical testing assets from Fresenius Medical Care’s Spectra Laboratories. This acquisition positions Quest to provide dialysis-related clinical testing to independent dialysis clinics previously served by Spectra. Under a separate agreement, Quest began offering comprehensive laboratory services to Fresenius Medical Care’s U.S. dialysis centers, which serve approximately 200,000 patients annually. This move is expected to enhance Quest’s capabilities in managing chronic kidney disease diagnostics.

Financial Outlook and Market Position

The company’s strong financial performance and strategic initiatives have bolstered its market position. In the fourth quarter of 2025, Quest reported revenues of $2.81 billion, a 7.1% increase from 2024, and a reported diluted EPS of $2.18, up 11.8% from the previous year. For the full year 2025, revenues reached $11.04 billion, an 11.8% increase from 2024, with a reported diluted EPS of $8.75, up 13.8%. The company also increased its quarterly dividend by 7.5% to $0.86 per share, reflecting confidence in its financial health and commitment to shareholder returns.

Conclusion

Quest Diagnostics’ recent financial results and strategic collaborations underscore its commitment to growth and innovation in the diagnostic information services sector. The company’s proactive approach to expanding its service offerings and enhancing operational efficiency positions it well for sustained success in the evolving healthcare landscape.